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A b s T r A C T
background: Chronic hepatitis C virus (HCV) is 
transmitted by blood-blood contact and this leads to high 
HCV prevalence in risk populations such as haemophilia 
patients and intravenous drug users. The prevalence in the 
general dutch population is unknown, although it appears 
to be very low in screened blood donors (0.0169%).
Aim: The objective of this study is to estimate the 
prevalence of HCV in a general population sample living 
in an urbanised region in the Netherlands. 
Methods: We randomly selected 2200 EdTA blood samples 
that had been submitted for analysis of biochemical 
parameters to a regional servicing laboratory for general 
practitioners (sHo, Arnhem/Nijmegen, the Netherlands). 
HCV antibody testing was performed using a three-step 
approach. for initial screening, an enzyme immunoassay 
(bioelisa HCV 4.0, biokit, spain) was used. Positive 
samples were subjected to a second, microparticle 
enzyme-linked immunoassay (AxsYM HCV version 3.0, 
Abbott laboratories, il, UsA). Genotypes were determined 
by line Probe Assay. 
results: A total of four persons (two females, two males) 
(0.2%) tested positive for HCV antibodies. The average od/
cut-off ratio of the screening assay was 2.9 (range 1.0 to 7.3) 
and serological findings were confirmed using a specific 
second immunoassay. HCV rNA (genotype 1b) was found 
in the sera of two persons.
Conclusion: The HCV prevalence in our sample of the 
dutch population was 0.2% which accords with earlier 
estimates from prevalence studies in the Netherlands.
K E Y W o r d s
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b A C K G r o U N d
Hepatitis C virus (HCV) is mainly transmitted through 
contact with blood and blood products. The majority of 
HCV-seropositive individuals will have persistent viraemia. 
More than half of all patients will develop chronic hepatitis, 
and in 20% infection will lead to cirrhosis with all the 
subsequent complications, such as ascites, encephalopathy, 
variceal bleeding and hepatocellular carcinoma.1 Chronic 
HCV infection often runs an asymptomatic course and only 
25 to 30% of infected persons seek medical attention for 
symptoms attributable to HCV infection.2 Early detection 
is of key importance in order to prevent complications of 
HCV-related liver disease. The WHO estimates that 3% of 
the world’s population is HCV-infected and in the USA 
it is a leading cause of liver transplantations.3,4 It is thus 
a significant clinical problem. However, there is wide 
variation in HCV prevalence in different parts of the world. 
For example, the prevalence in Scandinavia is less than 
0.5%, whereas the prevalence in Egypt is over 20%.5
In the UK, the number of new HCV diagnoses rose from 
2116 in 1996 to 7580 in 2005. Hospital admissions, 
transplants, and deaths related to HCV increased, and 
deaths from end-stage liver disease rose from 76 in 1997-8 
to 216 in 2004-5. These results suggest that the number 
of people at risk for HCV-associated morbidity or mortality 
will double over the next decade in the UK.6,7
In the Netherlands there have been only a few studies 
that focus on the prevalence of HCV. These studies 
were generally limited to high-risk populations, such as 
intravenous drug users and haemophilia patients. Some 
54% of Dutch haemophilia patients are HCV carriers, and 
up to 74% of iv drug users are infected.8 In 2000, two 
nationwide prospective surveys among 2281 and 2286 
dialysis patients resulted in an HCV prevalence of 2.9 and 
3.4%, respectively.9 
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The prevalence in the general population is estimated 
to be much lower (0.1 to 0.4%). However, this is a crude 
estimation based on extrapolation of the prevalence among 
selected high- and low-risk groups.10,11 Thus, the actual 
prevalence in the population at large is unknown, hence 
the need for population-based serological studies. These 
data are desirable because they allow medical professionals 
and policymakers to develop and evaluate efforts with 
respect to treatment and prevention. 
Therefore, the aim of this study is to determine the 
prevalence of HCV infection and the distribution of 
genotypes in the general Dutch population in urbanised 
regions of the East-Netherlands.
M A T E r i A l s  A N d  M E T H o d s
Patients and setting
Data for the present study were collected prospectively from 
2200 persons visiting general practices in the urbanised 
regions of Arnhem/Nijmegen in June 2006.
Patients had been referred to a servicing laboratory 
(SHO) by the general practitioner for analysis of 
biochemical parameters. After determination of the 
desired parameters, the remaining blood samples were 
stored at 4°C until transport to the laboratory of Radboud 
University Medical Centre in Nijmegen. All aspects of 
the protocol were reviewed and approved by the local 
medical ethical committee (CMO) Arnhem/Nijmegen, 
the Netherlands.
laboratory methods
Immediately after arrival to the laboratory, samples were 
centrifuged. Sera were then stored in aliquots at -80°C. 
Antibody testing
HCV antibody testing was performed using a three-step 
approach. For initial screening, an enzyme immunoassay 
(bioelisa HCV 4.0, Biokit, Barcelona, Spain) was used. 
Microtitre plates are coated with recombinant HCV 
antigens including core, NS3, NS4 and NS5. The 
cut-off value was determined by multiplying the mean 
optical density (OD) value of the low positive control 
by 0.9. Ratios of sample OD value and cut-off value 
of >1 were considered positive. Positive samples were 
further tested by a second, commonly used microparticle 
enzyme-linked immunoassay (AxSYM HCV version 3.0, 
Abbott Laboratories, IL, USA), because the Biokit assay 
is considered as sensitive as the AxSYM but somewhat 
less specific according to the information supplied by the 
manufacturer. Positive results in the AxSYM assay were 
then further tested using a recombinant immunoblot 
assay (INNO-LIA HCVTM Score, Innogenetics NV, Gent, 
Belgium). 
Hepatitis C rNA detection and genotyping
Antibody positive samples were tested for the presence 
of viral RNA and the HCV genotype. For isolation of 
HCV RNA the COBAS® AmpliPrep (Roche Molecular 
Systems, Branchburg, USA) was used according to the 
manufacturer’s instructions. Isolated HCV RNA was 
detected using the COBAS® TaqMan® HCV Analyzer real 
time PCR. Results are given in IU/ml. The detection range 
lies between 15 and 7 x 107 IU/ml. Hepatitis C genotype 
was determined using a Line Probe Assay LiPA, based on 
sequence variations found in the 5’ untranslated region of 
the different HCV genotypes (VERSANT HCV Genotype 
Assay, Bayer HealthCare LLC, USA) as described before.12 
All assays were performed according to the manufacturer’s 
instructions.
statistical analysis
Quantitative results are reported as the mean ± standard 
deviation, and qualitative results are given as percentages. 
For comparison of proportions between groups, x2, Fisher 
tests and independent T-tests were used. If a p value 
was below 0.05, the difference between proportions was 
considered statistically significant.
r E s U l T s 
In total 2200 subjects were tested on HCV antibodies. 
This group consisted of 1254 (57%) females and 928 
(42.2%) males with a mean age of 60.4 years (SD = 16.6). 
Demographical data on 18 patients were lacking, but they 
tested HCV negative using our testing strategy. Figure 
1 shows the strategy we followed to determine the HCV 
positivity.
figure 1. Flowchart of strategy to determine hepatitis  
C virus (HCV) positivity
2200 random selected 
blood samples
Bioelisa HCV 4.0, 
Biokit
2182 negative for 
HCV antibodies
AxSYM HCV 
version 3.0
Immunoblot 
assay
16 positive; 2 ambiguous 
for HCV antibodies
7 positive HCV 
antibodies
4 positive HCV 
antibodies
11 negative for 
HCV antibodies
3 negative for 
HCV antibodies
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In the initial screening using the Biokit assay, 16 out of 
2200 (0.7%) subjects had a positive test result with OD 
values varying from 1.016 to 8.466. Results from two 
additional samples were ambiguous with values of 0.919 
and 0.949. There were no significant differences with 
respect to age and gender of subjects between those with a 
positive and those with a negative ELISA (p=ns) (table 1).
conducted in high-risk groups or in blood donors, which 
may over- or under-estimate the actual burden of HCV 
infection in the general population. How do these data 
compare with other studies in this field?
The prevalence (0.2%) from this study is appreciably higher 
compared with healthy blood donors from the Netherlands. 
In 2001 approximately 0.0169% of new blood donors tested 
positive for HCV antibodies.13 In comparison, the HCV 
prevalence rates among healthy blood donors range from 
0.01 to 0.02% in the North-Western Europe, to 1 to 5% in 
Southern Europe.14
While interpreting these results, it is important to realise 
that blood donors are a self-selected group of individuals 
who have lower rates of blood-borne infections compared 
with the general population. Many of the people with risk 
factors for infection due to HCV (parenteral drug addiction, 
previous history of hepatitis) are rejected as blood donors. 
Therefore, these prevalence rates probably underestimate 
the actual HCV carrier rate. 
To this end, in another Dutch study a nationwide call was 
sent out for volunteers to give sera. The general public 
was invited by postal request to donate blood samples and 
the study went to great lengths to obtain a well-balanced 
age mix among the different geographic regions. This 
study measured HCV antibodies among a sample of 7373 
volunteers and found that only six tested anti-HCV positive 
(0.08%).15,16 When we combined this dataset with our 
own data, the cohort now encompasses a sample of 9573 
patients and yields an HCV prevalence of 0.10% (95% CI 
0.039 to 0.17%). 
In our study, we analysed sera obtained from subjects who 
underwent blood analysis for various reasons requested 
by their general practitioners in the Arnhem/Nijmegen 
region. This is a potential source of bias as we selected 
subjects who had a reason to go to their general practitioner 
and have blood taken. However, blood analysis in primary 
care is a common procedure, often used for the exclusion of 
severe disorders or for the reassurance of the physician or 
the patient that there is no severe pathology of underlying 
symptoms. 
As the incidence of serious diseases is low in the general 
practice population, it can be assumed that the observed 
prevalence of HCV is representative for the general 
population.17-19
This study was performed in the eastern part of the 
Netherlands, which is an urban region with a smaller 
immigration population of 13.7% in Gelderland compared 
with 25.1% in the Utrecht/North-Holland/South-Holland 
regions, which may affect the findings.20
Anti-HCV testing is performed in different settings, 
including hospitals, other healthcare facilities and also 
for screening purposes. Therefore the most desirable 
HCV screening is the test that has a very high specificity. 
Table 1. Anti-hepatitis C virus (HCV) prevalence tests 
according to gender and age
HCV test 1 HCV test 2
Negative
(n=2166)
Positive
(n=16)
Negative
(n=2178)
Positive
(n=4)
Age* 
(mean/SD)
60.4 (16.6) 61.4 (17) 60.4 (16.6) 60.0 (16.1)
n% females** 1244 (57.1) 10 (0.8) 1252 (57.5) 2 (50)
n% males** 922 (42.3) 6 (0.6) 926 (42.5) 2 (50)
*No age information about zeven subjects, **no gender information 
about 11 subjects.
These 16 positive and two ambiguous samples were 
subjected to further testing using an AxSYM assay. This 
established the presence of HCV antibodies in seven out 
of 16 positive samples (OD values of 37.36 to 82.82). Next 
we performed an immunoblot assay to confirm the HCV 
infection and were able to confirm the presence of specific 
anti-HCV antibodies in these four samples (two males, two 
females). Thus, the HCV prevalence in this sample can be 
estimated at 0.2%. Lastly, we searched for HCV RNA in 
these samples and detected viral RNA in two out of four 
samples. Both samples contained genotype 1b. 
In order to test the robustness of our findings, we designed 
a novel study using our cohort and the dataset of an 
earlier study as a replication cohort.15,16 We detected a 
positivity rate of 4/2200 while the other study found 6/7373 
positive.15,16 Next we calculated whether both datasets were 
statistically different. Using Fisher’s exact test we found 
that they were not (p=0.2). Subsequently we combined 
the datasets which yield a much larger cohort of 9573, 
containing ten HCV-positive patients. The new prevalence 
was 0.10%, with a calculated 95% confidence interval of 
0.039 to 0.17%.
d i s C U s s i o N
We performed a cross-sectional study to assess the 
epidemiology of HCV infection and we were able to 
estimate the prevalence at 0.2% among the general 
population residing in the eastern part of the Netherlands. 
Most of the previous research in this field had been 
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Consequently, this might lead to a lower sensitivity. 
Therefore in line with recommendations published 
elsewhere we decided to perform a second confirmatory 
ELISA in the positive samples.21 Indeed, this was beneficial 
as it led to exclusion of the suspicion of HCV infection in 
nine of the 16 samples (56%).
It is possible that a larger sample would have led to 
different results but in view of the abovementioned 
studies it is probable that the real HCV prevalence in the 
Netherlands is well below 0.5%, though we cannot exclude 
that there is a wide region-region variation. 
Other possible limitations include the absence of detailed 
information on whether these patients were aware of their 
infection and whether they had had treatment. In addition, 
HCV RNA could not be detected in two of the four subjects 
with HCV-positive antibodies. This can be explained by a 
decline in viral load during storage of the tubes or because 
the two subjects had cleared the HCV. It is known that 
around 20% of patients spontaneously clear HCV.4
The genotypes detected in our sample (1b) is the most 
common genotype in the Netherlands. A recent study 
performed by de Vries et al. showed that genotype 1 is 
found in approximately 50% of HCV patients in the 
Netherlands.22
How does this prevalence compare with other countries? 
In the USA, the prevalence of HCV infection is estimated 
at 1.6%.3 Various studies performed throughout Europe 
on the prevalence of HCV in general population indicate 
prevalences from 0.63% in Germany, 0.9% in Belgium 
to 1.2% in France.23-25 In Southern Europe the prevalence 
varies from 1.6% in Spain to 4.8 to 26.0% in Italy.26,27 The 
HCV prevalence is higher in Southern Italy compared 
with Northern Italy. The large variation is most probably 
due to differences in the quality of the healthcare system. 
In the recent past, healthcare facilities in Southern 
Italy made extensive use of glass syringes, and/or 
non-sterile syringe use facilitating nosocomial HCV 
transmission.28
Our results show lower HCV infection rates in the Dutch 
population compared with those found in other countries 
in Europe. Further, this accords with a North-South 
gradient in HCV prevalence in Europe. 
C o N C l U s i o N
The current study provides information on HCV prevalence 
in the general population. We found an HCV prevalence of 
0.2% in the general population. Combining our data with 
other observations provides a point estimate of 0.10%, 
with a 95% confidence interval of 0.039 to 0.17%, which is 
clearly lower than in other European countries. 
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New developments in the treatment of 
systemic lupus erythematosus
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Systemic lupus erythematosus (SLE) is the prototype of 
a systemic autoimmune disease. Many organ systems 
can be affected and a multitude of autoantibodies 
can be present. Although the aetiopathogenesis of 
the disease has not been fully elucidated yet, there 
is increasing evidence that genetic factors, next to 
environmental influences, play a major role. Certain 
polymorphisms in genes that are involved in immune 
responsiveness appear to be skewed in lupus. In recent 
years particular attention has been given to the role 
of apoptosis in lupus. Defective clearance of apoptotic 
cells leads to accumulation of these cells. In addition, 
intracellular antigens are, whether or not in modified 
form, expressed on the surface of these apoptotic cells. 
Handling of these (antigenetically modified) apoptotic 
cells by macrophages/dendritic cells may result in 
(auto)immune responses to these intracellular antigens. 
Thus, together with other developments, new insights 
have been gained into the pathogenesis of SLE.
Besides these breakthroughs in pathogenesis, new 
treatment modalities have become available for SLE. 
Although corticosteroids and immunosuppressives are 
still the mainstay of treatment in SLE, biologicals are 
now being tested with great promise for the future. As 
mentioned, aberrant B-cell activity with production of 
numerous autoantibodies appears to underlie many 
clinical characteristics of lupus. B-cell targeting via 
monoclonal antibodies in various forms is now a realistic 
goal in SLE. Interference in co-stimulation by small 
molecules or blocking B-cell activating factors is another 
way of inhibiting (autoreactive) B-cells. So, the horizon is 
open for many new exciting clinical trials in SLE.
All of these new developments in pathogenesis and 
treatment of SLE will be discussed in depth during the 
Seventh European Lupus Meeting that will be held in 
Amsterdam, 7-10 May 2008. The programme promises 
exciting news on autoimmunity in general and SLE in 
particular. For more information: www.lupus2008.nl.
